Cargando…
Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory
Cancer stem cells (CSCs) have drawn much attention as important tumour-initiating cells that may also be crucial for recurrence after chemotherapy. Although the activity of CSCs in various forms of cancer is complex and yet to be fully elucidated, opportunities for therapies targeting CSCs exist. CS...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003410/ https://www.ncbi.nlm.nih.gov/pubmed/36902427 http://dx.doi.org/10.3390/ijms24054997 |
_version_ | 1784904600885657600 |
---|---|
author | Artusa, Valentina Calabrone, Luana Mortara, Lorenzo Peri, Francesco Bruno, Antonino |
author_facet | Artusa, Valentina Calabrone, Luana Mortara, Lorenzo Peri, Francesco Bruno, Antonino |
author_sort | Artusa, Valentina |
collection | PubMed |
description | Cancer stem cells (CSCs) have drawn much attention as important tumour-initiating cells that may also be crucial for recurrence after chemotherapy. Although the activity of CSCs in various forms of cancer is complex and yet to be fully elucidated, opportunities for therapies targeting CSCs exist. CSCs are molecularly distinct from bulk tumour cells, so they can be targeted by exploiting their signature molecular pathways. Inhibiting stemness has the potential to reduce the risk posed by CSCs by limiting or eliminating their capacity for tumorigenesis, proliferation, metastasis, and recurrence. Here, we briefly described the role of CSCs in tumour biology, the mechanisms involved in CSC therapy resistance, and the role of the gut microbiota in cancer development and treatment, to then review and discuss the current advances in the discovery of microbiota-derived natural compounds targeting CSCs. Collectively, our overview suggests that dietary intervention, toward the production of those identified microbial metabolites capable of suppressing CSC properties, is a promising approach to support standard chemotherapy. |
format | Online Article Text |
id | pubmed-10003410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100034102023-03-11 Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory Artusa, Valentina Calabrone, Luana Mortara, Lorenzo Peri, Francesco Bruno, Antonino Int J Mol Sci Review Cancer stem cells (CSCs) have drawn much attention as important tumour-initiating cells that may also be crucial for recurrence after chemotherapy. Although the activity of CSCs in various forms of cancer is complex and yet to be fully elucidated, opportunities for therapies targeting CSCs exist. CSCs are molecularly distinct from bulk tumour cells, so they can be targeted by exploiting their signature molecular pathways. Inhibiting stemness has the potential to reduce the risk posed by CSCs by limiting or eliminating their capacity for tumorigenesis, proliferation, metastasis, and recurrence. Here, we briefly described the role of CSCs in tumour biology, the mechanisms involved in CSC therapy resistance, and the role of the gut microbiota in cancer development and treatment, to then review and discuss the current advances in the discovery of microbiota-derived natural compounds targeting CSCs. Collectively, our overview suggests that dietary intervention, toward the production of those identified microbial metabolites capable of suppressing CSC properties, is a promising approach to support standard chemotherapy. MDPI 2023-03-05 /pmc/articles/PMC10003410/ /pubmed/36902427 http://dx.doi.org/10.3390/ijms24054997 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Artusa, Valentina Calabrone, Luana Mortara, Lorenzo Peri, Francesco Bruno, Antonino Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory |
title | Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory |
title_full | Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory |
title_fullStr | Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory |
title_full_unstemmed | Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory |
title_short | Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory |
title_sort | microbiota-derived natural products targeting cancer stem cells: inside the gut pharma factory |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003410/ https://www.ncbi.nlm.nih.gov/pubmed/36902427 http://dx.doi.org/10.3390/ijms24054997 |
work_keys_str_mv | AT artusavalentina microbiotaderivednaturalproductstargetingcancerstemcellsinsidethegutpharmafactory AT calabroneluana microbiotaderivednaturalproductstargetingcancerstemcellsinsidethegutpharmafactory AT mortaralorenzo microbiotaderivednaturalproductstargetingcancerstemcellsinsidethegutpharmafactory AT perifrancesco microbiotaderivednaturalproductstargetingcancerstemcellsinsidethegutpharmafactory AT brunoantonino microbiotaderivednaturalproductstargetingcancerstemcellsinsidethegutpharmafactory |